From: HLA-B8 association with late-stage melanoma – an immunological lesson?
B8 | 16.22% | 20.33% | 4.12% | 0.0079 | * | 0.76 | 0.6184 to 0.9302 |
---|---|---|---|---|---|---|---|
HLA | melanoma | control | difference | p | sign. | OR | 95% ci OR |
B35 | 15.23% | 18.53% | 3.29% | 0.0273 | ns | 0.79 | 0.6409 to 0.9744 |
B7 | 27.79% | 25.34% | 2.45% | 0.1452 | ns | 1.13 | 0.9575 to 1.342 |
A9 | 23.68% | 21.42% | 2.26% | 0.1452 | ns | 1.14 | 0.9561 to 1.356 |
A10 | 11.23% | 13.33% | 2.1% | 0.1015 | ns | 0.82 | 0.6509 to 1.039 |
A26 | 5.01% | 6.98% | 1.97% | 0.0393 | ns | 0.70 | 0.5015 to 0.9846 |
B40 | 11.99% | 13.84% | 1.85% | 0.1624 | ns | 0.85 | 0.6728 to 1.070 |
B60 | 8.46% | 10.32% | 1.85% | 0.1123 | ns | 0.80 | 0.6133 to 1.053 |
B15 | 14.1% | 15.8% | 1.7% | 0.2266 | ns | 0.88 | 0.7047 to 1.087 |
A28 | 6.63% | 8.3% | 1.67% | 0.1076 | ns | 0.78 | 0.5834 to 1.055 |
B16 | 9.59% | 7.94% | 1.65% | 0.1151 | ns | 1.23 | 0.9504 to 1.591 |
B13 | 5.64% | 6.96% | 1.31% | 0.1762 | ns | 0.80 | 0.5774 to 1.108 |
A32 | 5.55% | 6.69% | 1.14% | 0.2232 | ns | 0.82 | 0.5939 to 1.132 |
B12 | 24.96% | 23.83% | 1.13% | 0.4902 | ns | 1.06 | 0.8930 to 1.266 |
A11 | 9.34% | 10.46% | 1.12% | 0.3308 | ns | 0.88 | 0.6839 to 1.137 |
A24 | 18.13% | 17.26% | 0.88% | 0.5401 | ns | 1.06 | 0.8761 to 1.287 |
A3 | 28.96% | 28.1% | 0.85% | 0.6122 | ns | 1.04 | 0.8856 to 1.228 |
B18 | 10.58% | 9.79% | 0.79% | 0.4900 | ns | 1.09 | 0.8526 to 1.395 |
A19 | 22.46% | 21.79% | 0.67% | 0.6671 | ns | 1.04 | 0.8705 to 1.242 |
B44 | 23.41% | 22.78% | 0.63% | 0.6942 | ns | 1.04 | 0.8666 to 1.238 |
A2 | 51.42% | 51.13% | 0.29% | 0.8768 | ns | 1.01 | 0.8724 to 1.173 |
A1 | 28.69% | 28.94% | 0.25% | 0.8825 | ns | 0.99 | 0.8385 to 1.163 |
B51 | 10.3% | 10.54% | 0.24% | 0.8361 | ns | 0.97 | 0.7598 to 1.249 |
B27 | 8.89% | 8.73% | 0.15% | 0.8884 | ns | 1.02 | 0.7814 to 1.329 |
A25 | 5.55% | 5.61% | 0.06% | 0.9429 | ns | 0.99 | 0.7151 to 1.366 |